Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren vs Amlodipine in Hypertensive Patients With Metabolic Syndrome
NCT00417170Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Mean Change in Endothelial Function as Measured by Myocardial Blood Flow (MBF) at 12 weeks. Started Oct 2007; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00417170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417170.